Acupuncture for Insomnia in Breast Cancer Patients Undergoing Chemotherapy (BCI)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04144309 |
|
Recruitment Status :
Recruiting
First Posted : October 30, 2019
Last Update Posted : April 21, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Insomnia, Secondary Breast Cancer Female Chemotherapy | Procedure: Electroacupuncture (EA) and Auricular Acupressure (AA) Procedure: Sham Electroacupuncture (SE) and Sham Auricular Acupressure (SA) | Not Applicable |
Insomnia is a frequent and disturbing symptom among cancer patients. Studies have found that cancer treatments, particularly chemotherapy, are a major cause of cancer-related insomnia. However, insomnia is under-treated in most breast cancer patients because effective, safe evidence-based treatments are lacking.
Acupuncture has been used for thousands of years to treat various diseases, including insomnia. Our previous research demonstrated the efficacy and safety of acupuncture as a treatment for insomnia. However, the effect of acupuncture on insomnia in breast cancer patients who undergo chemotherapy has been rarely studied. We propose this randomized controlled trial to examine the feasibility, effect and safety of acupuncture as a treatment for insomnia in breast cancer patients who undergo chemotherapy.
Hypothesis: We hypothesize that acupuncture is a feasible, effective and safe method for the alleviation of insomnia symptoms in breast cancer patients undergoing chemotherapy as compared with a sham control.
Primary Aim: To determine whether the insomnia condition in the acupuncture group is significantly improved when compared to the sham control group, as measured by the ISI after 6 weeks of treatment.
Secondary Aims: 1) To determine whether other sleep-related parameters in the acupuncture group improve more than those of the control group, as measured at different time points by Actiwatch, sleep diary, Pittsburgh Sleep Quality Index (PSQI), Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B), Hospital Anxiety and Depression Scale (HADS), Brief Fatigue Inventory (BFI) and Brief Pain Inventory (BPI). 2) To assess by adverse event (AE) analysis whether acupuncture is safe for treatment of insomnia in breast cancer patients undergoing chemotherapy.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 138 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | The Effect of Acupuncture for Insomnia in Breast Cancer Patients Undergoing Chemotherapy: A Randomized, Sham-Controlled Trial |
| Actual Study Start Date : | November 18, 2019 |
| Estimated Primary Completion Date : | October 2021 |
| Estimated Study Completion Date : | April 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: True acupuncture group
12 sessions of acupuncture treatment (EA+AA) will be given twice a week for 6 weeks after randomization, followed by once a month for 3 months, for a total of 15 sessions of treatments.
|
Procedure: Electroacupuncture (EA) and Auricular Acupressure (AA)
EA: Ten points will be used, including GV24 (Shenting), GV20 (Baihui), EX-HN1 (Sishenchong), PC6 (Neiguan), CV12 (Zhongwan), CV4 (Guanyuan), ST25 (Tianshu), ST36 (Zusanli), SP6 (Sanyinjiao), KI3 (Taixi). AA: Vaccaria seeds will be embedded by acupuncturists on three auricular points (Shenmen, Sympathetic and Heart) and maintained between EA treatments. |
|
Placebo Comparator: Sham acupuncture group
12 sessions of sham acupuncture treatment (SE+SA) will be given twice a week for 6 weeks after randomization, followed by once a month for 3 months, for a total of 15 sessions of treatments.
|
Procedure: Sham Electroacupuncture (SE) and Sham Auricular Acupressure (SA)
SE: The sham acupuncture treatment procedure, including the acupoint selection principle, sterilization procedure and treatment schedule, will be the same as in the acupuncture treatment group, except that sham points 1 to 2 cm exterior and inferior to the real points will be used, and no needle penetration or electric stimulation will be performed. SA: Three sham auricular points in the helix region (HX7, HX8, HX9) will be selected. Instead of Vaccaria seeds, soft Junci Medulla (1 to 2 mm in length, dyed black) will be used to mimic real AA with no pressure. |
- Insomnia Severity Index (ISI) [ Time Frame: Baseline, 3 week, 6 week, 10 week, 14 week, 18 week, 30 week, 42 week. ]The primary outcome will be the change of ISI score between the baseline and the end of the 6-week treatment. The ISI is a seven-item questionnaire devised to diagnose and assess the severity of insomnia.
- Actiwatch [ Time Frame: Baseline, 6 week. ]The subjects will wear Actiwatch for 1 week at baseline period and the end of 6-week treatment.
- Sleep diary [ Time Frame: Baseline, 6 week. ]Subjects will be given daily sleep diary for 1 week at baseline period and the end of 6-week treatment.
- Pittsburgh Sleep Quality Index (PSQI) [ Time Frame: Baseline, 3 week, 6 week, 10 week, 14 week, 18 week, 30 week, 42 week. ]The PSQI is a reliable and valid self-reported questionnaire that assesses sleep quality over 1 month.
- Hospital Anxiety and Depression Scale (HADS) [ Time Frame: Baseline, 3 week, 6 week, 10 week, 14 week, 18 week, 30 week, 42 week. ]The HADS, a 14-item self-rated questionnaire, evaluates the severity of depressive and anxiety symptoms.
- Brief Pain Inventory-Short Form (BPI-SF) [ Time Frame: Baseline, 3 week, 6 week, 10 week, 14 week, 18 week, 30 week, 42 week. ]The BFI is a brief screening tool designed to assess the severity and impact of cancer-related fatigue on daily functioning.
- Brief Fatigue Inventory (BPI) [ Time Frame: Baseline, 3 week, 6 week, 10 week, 14 week, 18 week, 30 week, 42 week. ]The BPI is a self-administered questionnaire designed to assess cancer pain.
- Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) [ Time Frame: Baseline, 3 week, 6 week, 10 week, 14 week, 18 week, 30 week, 42 week. ]The FACT-B is a patient-reported outcome measure used to assess health-related quality of life in breast cancer patients.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Female patients between 18 and 75 years of age.
- Diagnosis of stage (American Joint Committee on Cancer (AJCC) TNM) I-IV breast cancer.
- Currently receiving chemotherapy, or have completed chemotherapy no more than 6 months.
- Insomnia onset after the diagnosis of breast cancer.
- Insomnia occurs at least 3 nights per week, and presents for at least 1 month, with fulfilment of the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnostic criteria for brief insomnia disorder Insomnia severity as defined by an ISI score of no less than 10 in the past 2 weeks.
- Expected survival time of more than 6 months.
- Ability to understand the nature of the study and willingness to give informed consent.
- Ability to provide responses during outcome measurement.
Exclusion Criteria:
- Other sleep disorder (e.g., obstructive sleep apnoea).
- Shift work or irregular sleep pattern.
- Severe visual, hearing or language defects.
- Severe hematological dysfunction (platelet count <60,000/μL, haemoglobin <8 g/dL or absolute neutrophil count <1000/μL).
- History of acupuncture use in the previous 3 months.
- Participation in other clinical trials with intervention within 3 months of the beginning of the trial.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04144309
| Contact: Zhang-Jin ZHANG, MMed, PhD | +852 3917 6445 | zhangzj@hku.hk | |
| Contact: Jia-Ling ZHANG, M.B., M.Med | +852 9249 3025 | zhangjl0@hku.hk |
| Hong Kong | |
| Department of Clinical Oncology, Queen Mary Hospital | Recruiting |
| Hong Kong, Hong Kong, 999077 | |
| Contact: Tsz-Him SO, MBBS, BCM +852 2255 4352 sth495@hku.hk | |
| Principal Investigator: Tsz-Him SO, MBBS, BCM | |
| Hong Kong Sanatorium & Hospital | Recruiting |
| Hong Kong, Hong Kong, 999077 | |
| Contact: Tien-Yee CHANG, MBBS, PDipID +852 2255 7999 Amy.TY.Chang@hksh.com | |
| Principal Investigator: Tien-Yee CHANG, MBBS, PDipID | |
| Principal Investigator: | Zhang-Jin ZHANG, MMed, PhD | The University of Hong Kong |
Other Publications:
| Responsible Party: | Prof. Zhang Zhang-Jin, Professor, The University of Hong Kong |
| ClinicalTrials.gov Identifier: | NCT04144309 |
| Other Study ID Numbers: |
UW 19-045 |
| First Posted: | October 30, 2019 Key Record Dates |
| Last Update Posted: | April 21, 2020 |
| Last Verified: | April 2020 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Acupuncture Insomnia Breast cancer Chemotherapy |
|
Breast Neoplasms Sleep Initiation and Maintenance Disorders Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |
Sleep Disorders, Intrinsic Dyssomnias Sleep Wake Disorders Nervous System Diseases Mental Disorders |